EDIT-301 Program Update: RUBY and EdiTHAL Trial Data Update. Presented in a Company-sponsored Webinar. December 11, 2023.

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences